A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

NCT00752037 ·Status: COMPLETED ·Phase: PHASE4

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

NCT02238314 ·Status: COMPLETED ·Phase: PHASE2

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

NCT00002239 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

NCT00038220 ·Status: COMPLETED ·Phase: PHASE2

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

NCT02251223 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

NCT01602822 ·Status: TERMINATED ·Phase: PHASE4

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00358917 ·Status: COMPLETED ·Phase: PHASE3

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

NCT02239835 ·Status: TERMINATED ·Phase: PHASE2

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

NCT00004581 ·Status: COMPLETED ·Phase: PHASE3

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

NCT00530920 ·Status: COMPLETED ·Phase: PHASE2

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

NCT00034866 ·Status: COMPLETED ·Phase: PHASE2

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227 ·Status: COMPLETED ·Phase: PHASE4

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

NCT00357188 ·Status: COMPLETED ·Phase: PHASE1

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00262522 ·Status: COMPLETED ·Phase: PHASE3

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

NCT00440947 ·Status: COMPLETED ·Phase: PHASE3

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

NCT00043966 ·Status: COMPLETED ·Phase: PHASE3

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

NCT00838162 ·Status: COMPLETED ·Phase: PHASE2

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

NCT01896622 ·Status: COMPLETED ·Phase: PHASE1

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482 ·Status: TERMINATED ·Phase: PHASE1

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393 ·Status: COMPLETED ·Phase: PHASE3

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

NCT00121017 ·Status: WITHDRAWN ·Phase: PHASE2

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

NCT00931463 ·Status: COMPLETED ·Phase: PHASE4

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

NCT00027339 ·Status: COMPLETED ·Phase: PHASE2

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

NCT00002364 ·Status: COMPLETED ·Phase: PHASE2